Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. September 2018 07:00 ET | Quelle: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Corporate Organizational Changes

- Bryant D. Lim appointed as General Counsel and Secretary of the Board of Directors - - Chief Financial Officer Louis J. Arcudi III departing the company related to company consolidation to...
30. August 2018 07:30 ET | Quelle: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference

EXTON, Pa., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune...
09. August 2018 07:00 ET | Quelle: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals To Present at the 2018 Wedbush PacGrow Healthcare Conference

EXTON, Pa., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune...
02. August 2018 16:30 ET | Quelle: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Abstract accepted for 2018 European Society of Medical Oncology Annual Meeting Cash runway into first quarter of 2020 EXTON, Pa., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc....
27. Juli 2018 11:58 ET | Quelle: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces One-for-Eight Reverse Stock Split

EXTON, Pa., July 27, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune...
16. Juli 2018 07:00 ET | Quelle: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Provides Update on Corporate Strategy and Outlook

EXTON, Pa., July 16, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune...
10. Juli 2018 16:01 ET | Quelle: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Termination of Merger Agreement with BioCryst Pharmaceuticals

EXTON, Pa., July 10, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced today that the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) entered into...
12. Juni 2018 07:30 ET | Quelle: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Reports Results from Phase 2 Trial of IMO-8400 in Dermatomyositis

EXTON, Pa., June 12, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients...
04. Juni 2018 07:30 ET | Quelle: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Presents Clinical Data from the ILLUMINATE-204 Trial of the Combination of tilsotolimod and ipilimumab for Anti-PD-1 Refractory Metastatic Melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

- Data from Ongoing Phase 2 Study to be Presented at 1:15 PM CT at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting - - Of 21 patients evaluable for efficacy, 38% Overall...
09. Mai 2018 07:00 ET | Quelle: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update

EXTON, Pa., May 09, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and...

Vorherige Seite